Proactive Investors - Run By Investors For Investors

Genus upgraded to ‘buy’ by Peel Hunt after share placing

The placing proceeds will ensure balance sheet flexibility to continue to invest in the business and to take advantage of infill acquisition opportunities, Peel Hunt analysts said
Genus upgraded to ‘buy’ by Peel Hunt after share placing
Peel Hunt said the current share price was an attractive entry point into a high quality business

Genus PLC (LON:GNS) was upgraded to a ‘buy’ from a ‘hold’ rating by broker Peel Hunt after the animal genetics company said on Friday it had raised of £68mln through a share placing.

Genus said 3.1mln new shares were issued to new and existing investors at a price of 2,200p per placing share.

READ: Genus raises of £68mln through share placing

“The proceeds will ensure balance sheet flexibility to continue to invest in the business and to take advantage of infill acquisition opportunities,” Peel Hunt analysts wrote in a note to clients.

“The raise is slightly dilutive (c3% in the short term) but should be materially accretive as the company strengthens its strategic position and breeding capacity.”

Genus’s share price is 25% off the peak it reached last July, triggered by the outbreak of African swine fever (ASF) in China.

Peel Hunt said the current share price was an attractive entry point into a high-quality business with attractive long-term growth potential combined with the transformative opportunity in gene editing. Peel Hunt maintained its 2,600p target price.

Genus was earlier this week upgraded to a ‘buy’ from a ‘hold’ rating by broker Kepler Chevreux who believes the fall in the animal genetics company’s share price on the back of fears over the outbreak of African swine fever has been overdone.

Genus shares were 5.6% down at 2,258.0p in mid-morning trade.

View full GNS profile View Profile

Related Articles

genedrive device
Thu
Here we take a closer look at Genedrive PLC (LON:GDR)
1550834286_shutterstock_651647128.jpg
February 22 2019
The company is developing drugs for blood disorders, metabolic diseases and curbing alcohol use
Surgery
February 20 2019
Earlier this month, Tissue Regenix reported full-year results showing revenues more than doubled last year to £11.6mln, up from £5.2mln a year earlier
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use